Lung Cancer Clinical Trials

⁃ Aged greater than or equal to (≥) 18 years or ≥ the local legal age of majority, as applicable, at the time of signing the main informed consent form (ICF).

⁃ Criteria for disease state in dose escalation and cohort-expansion:

• Tumor histologies during dose escalation (including potential participants in backfill cohort): Participants with histologically or pathologically confirmed locally advanced or metastatic solid tumors, who are either ineligible for or intolerant of standard therapies, have no approved therapy with demonstrated benefit available, or have exhausted all available standard therapies:

⁃ <!-- -->

⁃ Gastric adenocarcinoma.

⁃ Colorectal cancer (CRC).

⁃ Non-small cell lung cancer (NSCLC) (both squamous and non-squamous).

⁃ Head and neck squamous cell carcinoma (HNSCC). b) Tumor histologies during dose expansion: Participants will be eligible if they have histologically or pathologically confirmed, locally advanced or metastatic solid tumors, as follows:

⁃ 1\. Metastatic or advanced squamous or non-squamous NSCLC:

• Participants with no known activating mutations: have received platinum-based chemotherapy and anti-programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) for locally advanced or metastatic disease (chemotherapy and anti-PD-1/PD-L1 treatment can be received in combination or in sequence).

• Participants with a known activating mutation with an approved and accessible target therapy (including but not limited to epidermal growth factor receptor \[EGFR\], anaplastic lymphoma kinase, ROS proto-oncogene 1, receptor tyrosine kinase, v-raf murine sarcoma viral oncogene homolog B1V600, rearranged during transfection, mesenchymal epithelial transition \[MET\] exon 14 skipping mutation, neurotrophic tyrosine receptor kinase, and kirsten rat sarcoma G12C) should have received the respective targeted therapy and 1 line of platinum-based chemotherapy and anti-PD-1/PD-L1 (if appropriate).

• Participants should have received no more than 3 prior lines of therapies for locally advanced or metastatic cancer.

• 2\. CRC: adenocarcinoma

• Participants who have received or been intolerant to treatment with either trifluridine/tipiracil (TAS-102), regorafenib or fruquintinib. Participants who have been treated with all are permitted. Participants must also have been previously treated with standard approved therapies, such as: fluoropyrimidine-, oxaliplatin-, or irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) biological therapy, and, if rat sarcoma (RAS) wild-type, an anti-EGFR therapy or checkpoint inhibitors, as clinically appropriate.

• Participants should have received no more than 4 prior lines of therapies for locally advanced or metastatic cancer.

• 3\. Gastric adenocarcinoma

• Participants who have received or been intolerant to platinum/fluoropyrimidine doublet with or without anthracycline. Participants who are human epidermal growth factor receptor 2 (HER2) positive, PD-L1 positive or having microsatellite instability-high (MSI-H) should have received anti-HER2 and anti-PD-1/PD-L1 treatment, respectively.

• Participants should have received no more than 3 prior lines of therapies for locally advanced or metastatic cancer.

• 3\. Confirmed PD-L1 positive by an FDA approved, Conformité Européene (CE)-marked, or other health-authority equivalent test in local lab. If historical PD-L1 status is not available, participants are eligible for pre-screening.

• 4\. Tumor tissue: All participants must provide an existing formalin-fixed paraffin-embedded (FFPE) archival tumor sample taken within 24 months of the date of the main ICF. If the acquisition of FFPE blocks is not feasible, freshly cut slides from the eligible FFPE sample should be provided, and the slides need to have been cut within 3 months before the expected (Cycle 1 Day 1) C1D1. See the lab manual, which is provided separately, for further details. If an FFPE archival tumor sample is not available, tumor biopsy will be required before trial entry.

• 5\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Participants must have at least 1 lesion that meets the definition of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria (radiologically measured by the investigator). Lesions in previously irradiated areas (or other local therapy) should not be selected as measurable/target lesions, unless treatment was ≥12 months prior to start of treatment and/or there has been demonstrated progression in that particular lesion.

• 7\. Adequate bone marrow function as defined below:

‣ Absolute neutrophil count (ANC) ≥1,000/ microliters(μL),

‣ Platelet count ≥75,000/μL

‣ Hemoglobin ≥9.0 grams per deciliter (g/dL). 8. Adequate renal and liver function as defined below:

• <!-- -->

∙ Alanine aminotransferase (ALT)/ Aspartate aminotransferase (AST) less than equal to (≤) 3.0 × the upper limit of the normal range (ULN); for participants with hepatic metastases, ALT and AST)≤5 × ULN.

‣ Total bilirubin ≤1.5 × ULN, except for participants with Gilbert's syndrome, who may be enrolled if the conjugated bilirubin is within normal limits.

‣ Creatinine clearance ≥45 mL/minute (calculated by Cockcroft-Gault formula). 9. Clinically significant toxic effects of previous therapy have recovered to Grade 1 (per National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] v5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, and/or autoimmune endocrinopathies with stable endocrine replacement therapy.

∙ 10\. Suitable venous access for the collection of trial-required blood sampling. 11. Symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic for ≥14 days, and meet the following criteria at the time of enrollment:

• a) No concurrent treatment for CNS disease (for example, surgery, radiation, and corticosteroids ≥10 mg/d prednisone or equivalent).